Home/HbO2 Therapeutics/Igor Serov

IS

Igor Serov

Chief Financial Officer

HbO2 Therapeutics

Therapeutic Areas

Anemia Organ Transplantation Ischemia/Hypoxia Veterinary Medicine

HbO2 Therapeutics Pipeline

Drug	Indication	Phase
Hemopure (HBOC-201)	Acute anemia (surgical); Life-threatening anemia (expanded access)	Approved (ZA, RU); Expanded Access (US)
Oxyglobin	Canine Anemia	Approved (US, EU)

Leadership Team at HbO2 Therapeutics

Chief Executive Officer

Senior Director, Process Development

View full HbO2 Therapeutics profile